改良型血清学活动但临床静止的系统性红斑狼疮患者减量糖皮质激素后疾病复发与损伤累积风险:一项多国观察性队列研究
该多国前瞻性队列纳入1850例改良型血清学活动但临床静止(mSACQ)的系统性红斑狼疮(SLE)患者,评估泼尼松龙每减量1 mg/d与复发及损伤累积的风险。结果显示减量不增加总体或严重复发风险,抗疟药使用与复发风险降低相关,初始泼尼松龙>5 mg/d者减量与非剂量>3 mg/d者减量者:初始泼尼松龙>5 mg/d者减量损伤风险降低相关。作者认为谨慎减量可行且可减少激素用量。
要点
- mSACQ患者泼尼松龙每减1 mg/d不增加总体复发(aHR 1.02,95%CI 0.99-1.05)和严重复发(aHR 0.98,95%CI 0.96-1.004)风险。
- 抗疟药使用与复发风险降低相关。
- 初始泼尼松龙>5 mg/d者减量与非剂量>5 mg/d者减量者损伤累积风险降低相关(aHR 0.96,95%CI 0.93-0.99)。
核心结论
- 在mSACQ患者中,减量糖皮质激素不增加复发风险,抗疟药使用与复发风险降低相关,初始泼尼松龙>5 mg/d者减量与非剂量>5 mg/d者减量者损伤累积风险降低相关,作者认为谨慎减量可行并可减少激素使用。
研究设计与样本
- 多国纵向SLE队列,前瞻性收集2013年至2020年12个国家的数据,纳入1850例mSACQ患者,采用Cox比例风险模型评估泼尼松龙每减1 mg/d与后续复发或损伤累积的风险,并校正混杂因素,观察期2年,事件发生时删失。
主要发现
- 1850例mSACQ患者中,742例发生总体复发,271例发生严重复发,180例发生损伤累积。
- 泼尼松龙每减1 mg/d与总体复发风险无关(校正HR 1.02,95%CI 0.99-1.05),与严重复发风险无关(校正HR 0.98,95%CI 0.96-1.004)。
- 抗疟药使用与复发风险降低相关。
- 初始泼尼松龙>5 mg/d的患者中,减量与非剂量>5 mg/d者减量者损伤累积风险降低相关(校正HR 0.96,95%CI 0.93-0.99)。
临床怎么用
- 作者认为,在mSACQ患者中谨慎减量糖皮质激素是可行的,并可减少激素使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the risk of flare and damage accrual after tapering glucocorticoids (GCs) in modified serologically active clinically quiescent (mSACQ) patients with systemic lupus erythematosus (SLE). METHODS: Data from a 12-country longitudinal SLE cohort, collected prospectively between 2013 and 2020, were analysed. SLE patients with mSACQ defined as the state with serological activity (increased anti-dsDNA and/or hypocomplementemia) but without clinical activity, treated with ≤7.5 mg/day of prednisolone-equivalent GCs and not-considering duration, were studied. The risk of subsequent flare or damage accrual per 1 mg decrease of prednisolone was assessed using Cox proportional hazard models while adjusting for confounders. Observation periods were 2 years and censored if each event occurred. RESULTS: Data from 1850 mSACQ patients were analysed: 742, 271 and 180 patients experienced overall flare, severe flare and damage accrual, respectively. Tapering GCs by 1 mg/day of prednisolone was not associated with increased risk of overall or severe flare: adjusted HRs 1.02 (95% CI, 0.99 to 1.05) and 0.98 (95% CI, 0.96 to 1.004), respectively. Antimalarial use was associated with decreased flare risk. Tapering GCs was associated with decreased risk of damage accrual (adjusted HR 0.96, 95% CI, 0.93 to 0.99) in the patients whose initial prednisolone dosages were >5 mg/day. CONCLUSIONS: In mSACQ patients, tapering GCs was not associated with increased flare risk. Antimalarial use was associated with decreased flare risk. Tapering GCs protected mSACQ patients treated with >5 mg/day of prednisolone against damage accrual. These findings suggest that cautious GC tapering is feasible and can reduce GC use in mSACQ patients.
引用
- Katsumata Y, Inoue E, Harigai M, et al. Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study. Ann Rheum Dis. 2024. PMID: 38423757. doi:10.1136/ard-2023-225369
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。